Inclusion Criteria:

- Patients with CML in chronic phase, accelerated phase based on cytogenetic
abnormalities in addition to Philadelphia chromosome but with less than 5 % blasts,
or GIST taking imatinib

- Patients with life expectancy of at least 12 months; patients must be on imatinib at
time of study entry.

- Ability to sign informed consent and/or assent

Exclusion Criteria:

- Patients with a known parathyroid disorder; active thyroid disorder except stable,
replaced hypothyroidism; Cushing's syndrome; uncontrolled diabetes mellitus (could
have unexpected fluid, electrolyte and mineral shifts); sarcoidosis (elevated
calcitriol levels from granulomata); hypercalcemia of malignancy (i.e.,
PTHrP-mediated or extensive bone mets);known tumor-induced osteomalacia; Paget's
disease of bone; known X-linged or autosomal dominant hypophosphatemic
rickets/osteomalacia; known renal tubular disease (e.g., Fanconi's syndrome); chronic
GI malabsorption sydrome.

- Patients taking oral calcium in excess of calcium 750 mg and Vitamin D 400 mg daily
(ie, that contained in a single multivitamin). Patients taking more than these
amounts may be eligible for this study if vitamin and mineral supplementation in
excess of this is stopped for a minimum of 2 weeks prior to study entry.

- Patients taking oral or intravenous steroids, calcitonin, any selective estrogen
modulating agent such as tamoxifen or raloxifene, gallium nitrate, and other bone
seeking radionuceotides, any calcimimetic agent such as cinacalet.

- Patients who have had prior treatment with cisplatin, carboplatin, oxaliplatin,
ifosfamide, or cyclophosphamide.